E-Book, Englisch, Band 338, 470 Seiten, eBook
Reihe: Boston Studies in the Philosophy and History of Science
LaCaze / Osimani Uncertainty in Pharmacology
1. Auflage 2020
ISBN: 978-3-030-29179-2
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark
Epistemology, Methods, and Decisions
E-Book, Englisch, Band 338, 470 Seiten, eBook
Reihe: Boston Studies in the Philosophy and History of Science
ISBN: 978-3-030-29179-2
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
Part I. Epistemology.- 1. Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning.- 2. Causal Insights from Failure: Post-Marketing Risk Assessment of Drugs as aWay to Uncover Causal Mechanisms.- 3. Extrapolating from Model Organisms in Pharmacology.- 4. "Mechanistic Versus Statistical Extrapolation in Preclinical Research in Psychiatry: Challenging the Received View".- 5. Analogy-Based Inference Patterns in Pharmacological Research.- 6. "In Silico Clinical Trials: a Possible Response to Complexity in Pharmacology".- 7. "Uncertainty in Drug Discovery: Strategies, Heuristics and Technologies".- 8. “Caught in the Amber”: a Sketch of Chemical Underdetermination.- Part II. Methods.- 9. A Millian Look at the Logic of Clinical Trials.- 10. "Learning by Difference: Placebo Effects and Specific Efficacy in Pharmacological RCTs".- 11. "An Evidence-Hierarchical Decision Aid for Rankingin Evidence-Based Medicine".- 12. "Assessing Drug Safety Assessment: Metformin Associated Lactic Acidosis".- 13. Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer’s Measurement.- 14. "Modelling Individual Response to Treatment and its Uncertainty: a Review of Statistical Methods and Challenges for Future Research".- Part III. Decisions.- 15. Values in Pharmacology.- 16. "Humbug, the Council of Pharmacy and Chemistry, and the Origin of “the Blind Test” of Therapeutic Efficacy".- 17. On the Normative Foundations of Pharmaceutical Regulation.- 18. After Disclosure.- 19. Sex, Drugs, and how to Deal with Criticism—The Case of Flibanserin.